ATXI: Avenue Therapeutics, Inc. Stock

by  •  • Comments Off on ATXI: Avenue Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.88
Enterprise Value ($M) -0.68
Book Value ($M) 1.65
Book Value / Share 1.15
Price / Book 1.74
NCAV ($M) 1.65
NCAV / Share 1.15
Price / NCAV 1.74

Profitability (mra)
Return on Invested Capital (ROIC) -5.73
Return on Assets (ROA) -18.86
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 2.70
Current Ratio 2.70

Balance Sheet (mrq) ($M)
Current Assets 2.62
Assets 2.62
Liabilities 0.97
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
8 days ago 13D/A Fortress Biotech, Inc. 8.90 -94.94
9 days ago 13G Armistice Capital, Llc 7.21
05-02 13G/A Davidow Robert L 2.90 -98.69
01-02 13G/A Sabby Management, Llc 4.99 150.40

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-22 1,307 45,604 2.87
2024-11-21 1,905 6,228 30.59
2024-11-20 7,006 19,039 36.80
2024-11-19 4,624 17,274 26.77
2024-11-18 1,567 13,254 11.82

(click for more detail)

Similar Companies
ASRT – Assertio Holdings, Inc. ATNF – 180 Life Sciences Corp.
ATOS – Atossa Therapeutics, Inc. ATYR – aTyr Pharma, Inc.
AVTX – Avalo Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io